Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)
- Registration Number
- NCT00418587
- Lead Sponsor
- Medical University of South Carolina
- Brief Summary
The purpose of this study is to test the safety and effectiveness of different doses of vitamin D in patients with Systemic Lupus Erythematosus (SLE). A long term goal is to determine if vitamin D could be used as a treatment and/or preventative of SLE.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- SLE by ACR criteria (revised 1997)
- African American, participating in the SLE in Gullah Health (SLEIGH) Study
- Outpatient
- Stable disease with no BILAG A or B in any system for the past 4 weeks
- Stable prednisone (or equivalent corticosteroid) dose ≤ 20 mg/day for ≥ 4 weeks prior to study entry
- Baseline 25(OH)D concentration of < 30 ng/ml
- Willingness to discontinue other vitamin D supplements and/or multivitamins containing vitamin D while participating in the study
- Age 18 - 85 years
- Ability to complete questionnaires in English
- Ability to give informed consent
Exclusion Criteria
- Presence of hypercalcemia (>10.4 mg/dL), hypercalcuria (urinary calcium/creatinine ratio ≥ 0.8 mmol/mmol) or known primary hyperparathyroidism
- Liver disease (serum ALT, AST >2x normal) or total serum bilirubin >1.5x normal
- History of renal stones
- Current treatment with any dose of cyclophosphamide
- Dialysis or creatinine > 2.5 mg/dL
- Pregnancy
- Current drug or alcohol abuse
- Anticipated poor compliance
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Cholecalciferol 800 IU oral daily dose level 2 Cholecalciferol 2000 IU oral daily dose level 3 Cholecalciferol 4000 IU oral daily dose level
- Primary Outcome Measures
Name Time Method Hypercalcuria Monthly
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of cholecalciferol via VDR activation are relevant to SLE pathogenesis?
How does cholecalciferol compare to standard immunosuppressants in SLE disease activity reduction?
Which biomarkers, such as cytokine profiles or VDR expression, predict cholecalciferol response in SLE?
What are the hypercalcemia risks and management strategies for cholecalciferol in SLE Phase 1 trials?
Are there synergistic effects of cholecalciferol with hydroxychloroquine in SLE treatment strategies?
Trial Locations
- Locations (1)
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Medical University of South Carolina🇺🇸Charleston, South Carolina, United States